Amazon’s collusion with merchants drove up prices, California Attorney-General says

California’s attorney-general unsealed evidence in a 3.5-year antitrust suit alleging Amazon pressured merchants and rivals, including Walmart, Home Depot and Chewy, to raise prices on goods such as khaki pants, fertilizer, eye drops and dog treats. The state is seeking an injunction and ill-gotten profits, with trial set for Jan. 19, 2027 and a hearing scheduled for July 23. The allegations create meaningful legal and reputational risk for Amazon and could affect pricing practices across retail.

Analysis

This is not just an AMZN headline risk; it is a margin-structure risk. If regulators can credibly frame Amazon as the coordinating node that forces downstream sellers to choose between higher list prices and losing placement, the economic harm propagates beyond the marketplace fee line into the core Prime value proposition: consumers may begin to perceive Amazon as a price floor enforcer rather than a price comparator, which weakens conversion and increases the odds of shopping leakage to Walmart, Target, specialty verticals, and direct-to-consumer channels.

The second-order implication is that Amazon’s advertising and third-party services business is more exposed than headline retail margins. Any injunction or conduct remedy that reduces pricing coordination could compress marketplace take rates or reduce seller willingness to buy ancillary services, while a drawn-out case still creates a drag because merchants will diversify channel mix preemptively to avoid dependency. The biggest loser may be not the named rivals themselves but the long tail of brand owners that rely on Amazon for demand capture yet need multiple retailers to support price discipline; that fragmentation could raise fulfillment complexity and inventory buffers across the sector.

For the other names, the read-through is mixed. Walmart and Home Depot can absorb some incremental traffic if they choose to undercut Amazon, but they also risk being pulled into a lower-price equilibrium that caps gross margin expansion in categories where online price transparency is now more visible. Chewy’s exposure is more tactical: pet is highly repeat-purchase and price-elastic, so even a modest shift in comparative pricing can quickly redirect share, but the category’s logistics intensity limits how aggressively rivals can stay below Amazon for long. ABBV is essentially insulated unless the legal narrative broadens to pharmacy-style pricing conduct elsewhere; that makes the current setup more of a sentiment overhang than a fundamentals issue.

The contrarian view is that the market may overestimate near-term earnings damage and underestimate the multi-year duration. A 2027 trial means this is likely a headline-volatility event before it is an economic one, and most of the P&L impact should come from multiple compression and conduct-risk pricing rather than immediate revenue loss. If Amazon responds by loosening pricing pressure to look cooperative, that may actually improve reported gross margin in the next few quarters, creating a misleadingly positive tape even as regulatory risk worsens.

Key Decisions for Investors

• Short AMZN on regulatory headline bounces; use a 3-6 month horizon and size for multiple compression rather than earnings deterioration. Best risk/reward is on rallies that retrace the initial selloff, with a stop above the pre-news valuation range if market shrugs off the conduct risk.
• Pair trade: long WMT / short AMZN for 3-9 months. WMT has the cleanest relative-positioning benefit if consumers re-rate Amazon as less price-competitive, while AMZN carries the larger litigation overhang; expect the pair to work mainly through multiple dispersion, not immediate fundamental outperformance.
• Buy CHWY call spreads or a small equity long for the next 1-2 quarters. Pet category pricing is highly visible and Amazon friction can redirect repeat purchases quickly; cap downside with defined-risk options because category-scale competitors can still respond aggressively.
• Reduce exposure to AMZN-adjacent advertising and marketplace beneficiaries over the next 6-12 months if your book is long seller monetization. The trade is not a direct short of those names, but a hedge against any remedy that lowers marketplace economics and seller attach rates.
• Avoid chasing LEVI/HD as primary beneficiaries. Any uplift from price discipline is likely to be diluted by category-specific margin pressure; better expressed via relative shorts against AMZN than outright longs.